Copy to clipboard 
DJO Global posted 2Q18 revenue of US $304.8MM, +3.4% vs. 2Q17, and 1H18 revenue of $739.4MM, +5.0% vs. 1H17.
ORTHOWORLD estimates segment sales and growth as follows.
| 2Q18 | 2Q17 | $ Change | % Change | |
| Joint Reconstruction | $71.0 | $60.8 | $10.2 | 16.8% |
| Knee | $19.2 | $16.2 | $3.1 | 19.0% |
| Hip | $16.7 | $14.6 | $2.1 | 14.2% |
| Extremities | $35.0 | $30.0 | $5.1 | 16.8% |
| Other* | $233.9 | $233.9 | -$0.1 | 0.0% |
| Total | $304.8 | $294.7 | $10.1 | 3.4% |
| 1H18 | 1H17 | $ Change | % Change | |
| Joint Reconstruction | $142.0 | $121.0 | $21.0 | 17.3% |
| Knee | $38.5 | $32.2 | $6.3 | 19.6% |
| Hip | $33.4 | $29.1 | $4.3 | 14.8% |
| Extremities | $70.1 | $59.7 | $10.4 | 17.4% |
| Other * | $597.5 | $583.1 | $14.4 | 2.5% |
| Total | $739.4 | $704.0 | $35.4 | 5.0% |
*Includes Bracing/Vascular, Recovery Sciences and also International revenue not already attributed to Joint Recon
Revenue by geographic region:
| 2Q18 | 1H18 | |
| U.S. | $217.9 | $563.8 |
| Ex-U.S. | $87.0 | $175.6 |
DJO had a great quarter and half in Surgical Implants—in shoulders, specifically, citing growth of +19% for the quarter and +20% for the half. (Surgical Implants comprises hips, knees, shoulders, elbows, bone cement, etc. Please keep in mind that ORTHOWORLD estimates reflect a portion of International revenue from joint reconstruction products that is added to DJO’s Surgical Implant segment reporting. We always welcome comments on our estimates.)
The company commenced a series of product launches at the end of 2Q, with more planned in 3Q to fuel double-digit growth in hip and knee as well as the entire business. As noted in the 1Q18 call, DJO planned for seven surgical implant launches in 2018, with six slated for hip/knee.
Leadership highlighted continued sustainable value delivery from the company’s transformation efforts originally announced in the 2016 call. As planned, the company is on track to realize 7% to 10% in annual cost reductions by end of this year.
Sources: DJO Global, Inc.; ORTHOWORLD estimates
DJO Global posted 2Q18 revenue of US $304.8MM, +3.4% vs. 2Q17, and 1H18 revenue of $739.4MM, +5.0% vs. 1H17.
ORTHOWORLD estimates segment sales and growth as follows.
Q18
Q17
$ Change
% Change
Joint Reconstruction...
DJO Global posted 2Q18 revenue of US $304.8MM, +3.4% vs. 2Q17, and 1H18 revenue of $739.4MM, +5.0% vs. 1H17.
ORTHOWORLD estimates segment sales and growth as follows.
| 2Q18 | 2Q17 | $ Change | % Change | |
| Joint Reconstruction | $71.0 | $60.8 | $10.2 | 16.8% |
| Knee | $19.2 | $16.2 | $3.1 | 19.0% |
| Hip | $16.7 | $14.6 | $2.1 | 14.2% |
| Extremities | $35.0 | $30.0 | $5.1 | 16.8% |
| Other* | $233.9 | $233.9 | -$0.1 | 0.0% |
| Total | $304.8 | $294.7 | $10.1 | 3.4% |
| 1H18 | 1H17 | $ Change | % Change | |
| Joint Reconstruction | $142.0 | $121.0 | $21.0 | 17.3% |
| Knee | $38.5 | $32.2 | $6.3 | 19.6% |
| Hip | $33.4 | $29.1 | $4.3 | 14.8% |
| Extremities | $70.1 | $59.7 | $10.4 | 17.4% |
| Other * | $597.5 | $583.1 | $14.4 | 2.5% |
| Total | $739.4 | $704.0 | $35.4 | 5.0% |
*Includes Bracing/Vascular, Recovery Sciences and also International revenue not already attributed to Joint Recon
Revenue by geographic region:
| 2Q18 | 1H18 | |
| U.S. | $217.9 | $563.8 |
| Ex-U.S. | $87.0 | $175.6 |
DJO had a great quarter and half in Surgical Implants—in shoulders, specifically, citing growth of +19% for the quarter and +20% for the half. (Surgical Implants comprises hips, knees, shoulders, elbows, bone cement, etc. Please keep in mind that ORTHOWORLD estimates reflect a portion of International revenue from joint reconstruction products that is added to DJO’s Surgical Implant segment reporting. We always welcome comments on our estimates.)
The company commenced a series of product launches at the end of 2Q, with more planned in 3Q to fuel double-digit growth in hip and knee as well as the entire business. As noted in the 1Q18 call, DJO planned for seven surgical implant launches in 2018, with six slated for hip/knee.
Leadership highlighted continued sustainable value delivery from the company’s transformation efforts originally announced in the 2016 call. As planned, the company is on track to realize 7% to 10% in annual cost reductions by end of this year.
Sources: DJO Global, Inc.; ORTHOWORLD estimates
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
